Objective: This study is to investigate the clinical efficacy of EGFR inhibitors on mutations in lung cancer patients with EGFR 19 and 21 exons. Methods: A total of 178 lung cancer patients were selected from January 2012 to September 2016 in this study and their EGFR mutations were analyzed by Real-time PCR. Then the patients were divided into Exon 19 group (n = 89) and Exon 21 group (n = 89) according to EGFR mutation status, and being treated with EGFR inhibitor erlotinib. Finally, the clinical efficacy and safety of the two groups were analyzed. Results: The average age of patients in Exon 19 group was lower than that of Exon21 group (P <0.05). The response Rate (RR) of the Exon19 group was 51.69%, while the RR of the Exon21 group was 48.31% (P> 0.05). The median overall survival (OS) were 56.00 months (95CI%: 54.054,57.946) and 49.00 months(95CI%: 47.682, 50.316)in the Exon 19 group and Exon21 group respectively. The median Progression-free Survival (PFS) were 50.00 (95CI%: 47.529,52.471) and 41.00 (95CI%: 38.738,43.262)in the Exon 19 group and Exon21 group respectively. Furthermore, the incidence of adverse reactions was similar between the two groups (P> 0.05). Conclusion: Lung cancer patients with EGFR 19 exon mutation are younger than those with EGFR 21 exon mutations, which may get more benefits from EGFR inhibitor therapy.
IJCR is following an instant policy on rejection those received papers with plagiarism rate of more than 20%. So, All of authors and contributors must check their papers before submission to making assurance of following our anti-plagiarism policies.
